Key Highlights - Battalion Oil Corporation has continued its drilling operations, completing four wells in the Monument Draw area and drilling ahead of schedule on two additional wells in West Quito [2] - The company reported average daily net production of 11,900 Boe/d (53% oil) and total operating revenue of $47.5 million for Q1 2025, compared to 12,989 Boe/d (48% oil) and $49.9 million in Q1 2024 [4] - The acid gas injection facility treated approximately 18 MMcf/d on average during Q1 2025, with subsequent increases in daily rates to over 30 MMcf/d [3] Management Comments - The company is in the final stages of drilling operations on the last well of its six-well activity plan for 2025, with capital expenditures on the first well in West Quito approximately $1.0 million under AFE [2] - Recently completed wells in the Monument Draw field are expected to deliver over 1,000,000 barrels of oil ultimate recovery each [2] Results of Operations - Battalion reported a net loss available to common stockholders of $5.8 million, or a net loss of $0.35 per share for Q1 2025, compared to a net loss of $36.8 million, or $2.24 per share in Q1 2024 [6][12] - Adjusted EBITDA for Q1 2025 was $15.1 million, an increase from $9.4 million in Q1 2024 [6] Financial Performance - Lease operating and workover expenses increased to $11.01 per Boe in Q1 2025 from $10.55 per Boe in Q1 2024, primarily due to inflationary market increases [5] - General and administrative expenses rose to $4.12 per Boe in Q1 2025 from $3.44 per Boe in Q1 2024, driven by higher payroll and benefits costs [5] Liquidity and Balance Sheet - As of March 31, 2025, the company had $225.0 million in term loan indebtedness and total liquidity of $73.6 million [9] - Current assets increased to $111.4 million as of March 31, 2025, compared to $54.1 million a year earlier [14]

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against Zynex, Inc. (NASDAQ: ZYXI), a medical device manufacturer specializing in electrotherapy devices, alleging that the company and certain of its top executives misled investors by overstating revenue through the practice of shipping excessive and unnecessary supplies to patients. The complaint, Tuncel v. Zynex, Inc., No. 25-cv-00913, filed in the U.S. District Court for the District of Colorado, seeks to represent in ...

Financial Performance - The company declared a cash dividend of $0.05 per share for the quarter ended March 31, 2025, totaling $3.5 million, and plans to repurchase approximately $3.3 million of its common stock [1] - Total operating revenues for the three months ended March 31, 2025, were $151.4 million, a 12.9% increase from $134.2 million for the same period in 2024 [1] - Net income attributable to stockholders was $27.0 million for the three months ended March 31, 2025, compared to $22.6 million for the same period in 2024, reflecting a 19.8% increase [1][30] - EBITDA for the quarter was $74.3 million, up from $72.8 million in the prior year [1][30] - Basic earnings per share increased to $0.39 for the three months ended March 31, 2025, compared to $0.31 for the same period in 2024 [1][30] Operational Highlights - The average daily time charter equivalent (TCE) rate across the fleet was $30,476 for the three months ended March 31, 2025, compared to $28,339 for the same period in 2024 [3][36] - Fleet utilization remained strong at 92.4% for the three months ended March 31, 2025, compared to 89.3% for the same period in 2024 [4][36] - The company had an average of 30 vessels engaged under time charters and 20 vessels on spot voyage charters during the quarter [6] Debt and Liquidity - The company increased its debt by $48.6 million to $902.1 million during the three months ended March 31, 2025 [1] - As of March 31, 2025, the company had cash, cash equivalents, and restricted cash totaling $139.0 million [1][53] - The company entered into a Senior Secured Term Loan and Revolving Credit Facility for up to $300 million on May 2, 2025, to refinance existing loans and for general corporate purposes [14][55] Market Conditions - U.S. domestic ethylene prices were elevated at the beginning of the first quarter, reaching a high of $700 per metric ton in January, but fell to $450 per metric ton by the end of March 2025 [5] - The company’s share of results from the Ethylene Export Terminal showed a loss of $0.9 million for the three months ended March 31, 2025, compared to a gain of $4.4 million for the same period in 2024, primarily due to lower export volumes [10][48] Shareholder Returns - The company’s Return of Capital policy includes quarterly cash dividends and share repurchases, targeting a total return of at least 25% of net income for the applicable quarter [23][24] - A new share repurchase plan was authorized on May 13, 2025, allowing for the repurchase of up to $50 million of common stock [22]

Group 1 - Vinci Partners Investments Ltd. reported Q1 2025 earnings, marking the second quarter after the merger with Compass and the first with a complete three months of integration [1] - The company focuses on long-only investment strategies, evaluating companies from an operational and buy-and-hold perspective, rather than market-driven dynamics [1] - Quipus Capital emphasizes understanding the long-term earnings power of companies and the competitive dynamics of their industries, advocating for a cautious approach to investment [1] Group 2 - The article indicates that most investment calls will be holds, reflecting a design choice to maintain a healthy skepticism in a bullish market [1] - A very small fraction of companies are deemed suitable for a buy at any given time, highlighting a selective investment strategy [1]

Core Points - Logansport Financial Corp. has declared a quarterly cash dividend of $0.45 per share for the second quarter of 2025 [1] - The dividend is scheduled to be paid on July 14, 2025, to shareholders on record as of June 13, 2025 [1] Company Summary - Logansport Financial Corp. is the holding company for Logansport Savings Bank, a state commercial bank located in Logansport, Indiana [1]

FALLS CHURCH, Va., May 14, 2025 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) will conduct its annual shareholders meeting exclusively online on Wednesday, May 21 at 8 a.m. Eastern time. You may access the virtual meeting by following this link, or by visiting virtualshareholdermeeting.com/NOC2025. We will also provide a link to the virtual meeting on our investor relations webpage at http://investor.northropgrumman.com. A replay will be available for two weeks following the meeting. If you a ...

Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstracts for poster presentation at the ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024). Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to the growing interest of institutional and individual shareholders, fi ...

SINGAPORE, May 14, 2025 /PRNewswire/ -- Canaan Inc. (NASDAQ: CAN) ("Canaan" or the "Company"), an innovator in crypto mining, today released its unaudited bitcoin mining update for the month ending April 30, 2025.Management Commentary"Our April production metrics demonstrate our ability to maintain a cost-effective mining operation on a global scale, as we expand our footprint and grow our bitcoin holdings," said Nangeng Zhang, chairman and chief executive officer of Canaan. "Consistent with our policy, we ...

Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation co ...